Drug Metabolism Letters

Zhiyang Zhao
Amgen
Cambridge, MA
USA

Back

Metabolism of Loratadine and Further Characterization of Its In Vitro Metabolites

Author(s): Anima Ghosal, Samir Gupta, Ragu Ramanathan, Yuan Yuan, Xiaowen Lu, Ai Duen (Iris) Su, Narciso Alvarez, Shmuel Zbaida, Swapan K. Chowdhury, Kevin B. Alton.

Abstract:

The present study demonstrated that in addition to CYP3A4 and CYP2D6, the metabolism of loratadine is also catalyzed by CYP1A1, CYP2C19, and to a lesser extent by CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP3A5. The biotransformation of loratadine was associated with the formation of desloratadine (DL) and further hydroxylation of both DL and the parent drug (loratadine). Based on the inhibition and correlation studies contribution of CYP2C19 in the formation of the major circulating metabolite DL seems to be minor. Reported clinical results suggest that the steady state mean (%CV) plasma Cmax and AUC24hr of loratadine were 4.73 ng/ml (119%) and 24.1 ng.hr/ml (157%), respectively, after dosing with 10 mg loratadine tablets for 10 days. High inter-subject variability in loratadine steady-state data is probably due to the phenotypical characteristics of CYP2D6, CYP2C19, and CYP3A4. The relative abundance of CYP3A4 in the human liver exceeds that of CYP2C19 and CYP2D6 and therefore the contribution of CYP3A4 in the metabolism of loratadine should be major (∼70%).

Keywords: Loratadine, desloratadine, CYP3A4, CYP2D6, CYP2C19

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 3
ISSUE: 3
Year: 2009
Page: [162 - 170]
Pages: 9
DOI: 10.2174/187231209789352067
Price: $58